JP2010509931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509931A5 JP2010509931A5 JP2009537651A JP2009537651A JP2010509931A5 JP 2010509931 A5 JP2010509931 A5 JP 2010509931A5 JP 2009537651 A JP2009537651 A JP 2009537651A JP 2009537651 A JP2009537651 A JP 2009537651A JP 2010509931 A5 JP2010509931 A5 JP 2010509931A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- seq
- functional fragment
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0610329A FR2909092B1 (fr) | 2006-11-24 | 2006-11-24 | Nouveaux anticorps anti-proliferation |
| PCT/EP2007/062760 WO2008062063A1 (en) | 2006-11-24 | 2007-11-23 | Novel antiproliferation antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509931A JP2010509931A (ja) | 2010-04-02 |
| JP2010509931A5 true JP2010509931A5 (enExample) | 2011-01-20 |
Family
ID=37903981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537651A Ceased JP2010509931A (ja) | 2006-11-24 | 2007-11-23 | 新規抗増殖性化合物 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8071730B2 (enExample) |
| EP (1) | EP2074148A1 (enExample) |
| JP (1) | JP2010509931A (enExample) |
| KR (1) | KR20090088878A (enExample) |
| CN (1) | CN101535344B (enExample) |
| AU (1) | AU2007324509B2 (enExample) |
| BR (1) | BRPI0719323A2 (enExample) |
| CA (1) | CA2670039A1 (enExample) |
| CL (1) | CL2007003357A1 (enExample) |
| CR (1) | CR10788A (enExample) |
| CU (1) | CU23792A3 (enExample) |
| EC (1) | ECSP099341A (enExample) |
| FR (1) | FR2909092B1 (enExample) |
| GE (1) | GEP20125629B (enExample) |
| GT (1) | GT200900126A (enExample) |
| IL (1) | IL198744A0 (enExample) |
| MA (1) | MA30891B1 (enExample) |
| MX (1) | MX2009005293A (enExample) |
| NI (1) | NI200900079A (enExample) |
| NO (1) | NO20092360L (enExample) |
| NZ (1) | NZ576174A (enExample) |
| RU (1) | RU2451689C2 (enExample) |
| SA (1) | SA07280637B1 (enExample) |
| TN (1) | TN2009000194A1 (enExample) |
| TW (1) | TW200829602A (enExample) |
| UA (1) | UA99602C2 (enExample) |
| WO (1) | WO2008062063A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| CN102596249A (zh) * | 2009-10-30 | 2012-07-18 | 默沙东公司 | Ax1和ax189 pcsk9拮抗剂和变体 |
| KR20140008308A (ko) * | 2010-10-29 | 2014-01-21 | 이뮤노젠 아이엔씨 | 신규한 egfr-결합 분자 및 이의 면역컨쥬게이트 |
| EP2455403A1 (en) | 2010-11-23 | 2012-05-23 | Pierre Fabre Medicament | Homogeneous humanized antibodies against JAM-A that inhibit proliferation |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20130287790A1 (en) * | 2012-03-30 | 2013-10-31 | The Board Of Trustees Of The Leland Standford Junior University | Use of jam-a in diagnosing and treating leukemia |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| CA2881966C (en) | 2012-08-24 | 2020-10-06 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| KR20150097304A (ko) | 2014-02-18 | 2015-08-26 | 삼성전자주식회사 | 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체 |
| KR20250065434A (ko) * | 2016-03-01 | 2025-05-12 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체 |
| EP3474854A4 (en) | 2016-06-27 | 2020-02-19 | The Regents of The University of California | CANCER TREATMENT COMBINATIONS |
| WO2018027039A1 (en) | 2016-08-03 | 2018-02-08 | Nextcure, Inc. | Compositions and methods for modulating lair signal transduction |
| CN109022366A (zh) * | 2018-08-16 | 2018-12-18 | 江南大学 | 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用 |
| EP4041392A1 (en) | 2019-10-08 | 2022-08-17 | Nectin Therapeutics Ltd. | Antibodies against the poliovirus receptor (pvr) and uses thereof |
| CN114740108B (zh) * | 2022-03-28 | 2023-07-14 | 天津键凯科技有限公司 | 一种聚合物修饰抗体类药物的修饰度的测定方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9604470D0 (sv) * | 1996-12-04 | 1996-12-04 | Tamas Bartfai Konsulting Ab | Transmembrane component of tight junction |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US20030171568A1 (en) * | 1998-09-16 | 2003-09-11 | Avi Ashkenazi | Use of A33 antigens and JAM-IT |
| TR200002885T2 (tr) * | 1998-04-03 | 2000-12-21 | Chugai Seiyaku Kabushiki Kaisha | İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor |
| ATE500328T1 (de) * | 1999-03-11 | 2011-03-15 | Merck Serono Sa | Vaskuläre adhesionsmoleküle und modulierung ihrer funktion |
| WO2005060457A2 (en) * | 2003-12-04 | 2005-07-07 | Pdl Biopharma, Inc. | Treatment of inflammatory bowel diseases with anti-ip-10 antibodies |
| WO2006008076A2 (en) * | 2004-07-16 | 2006-01-26 | Universita Degli Studi Di Milano | Methods and agents stimulating the immune response |
| EP1888639A1 (en) * | 2005-05-12 | 2008-02-20 | Oncotherapy Science, Inc. | Methods for damaging cells using effector function of anti-dsc2 antibody |
| AU2007243196A1 (en) * | 2006-04-28 | 2007-11-08 | Oregon Health & Science University | Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cell |
-
2006
- 2006-11-24 FR FR0610329A patent/FR2909092B1/fr not_active Expired - Fee Related
-
2007
- 2007-11-23 NZ NZ576174A patent/NZ576174A/en not_active IP Right Cessation
- 2007-11-23 GE GEAP200711322A patent/GEP20125629B/en unknown
- 2007-11-23 UA UAA200906473A patent/UA99602C2/ru unknown
- 2007-11-23 JP JP2009537651A patent/JP2010509931A/ja not_active Ceased
- 2007-11-23 AU AU2007324509A patent/AU2007324509B2/en not_active Ceased
- 2007-11-23 CN CN2007800405398A patent/CN101535344B/zh not_active Expired - Fee Related
- 2007-11-23 EP EP07847306A patent/EP2074148A1/en not_active Withdrawn
- 2007-11-23 MX MX2009005293A patent/MX2009005293A/es active IP Right Grant
- 2007-11-23 BR BRPI0719323-8A patent/BRPI0719323A2/pt not_active IP Right Cessation
- 2007-11-23 KR KR1020097009675A patent/KR20090088878A/ko not_active Ceased
- 2007-11-23 CL CL200703357A patent/CL2007003357A1/es unknown
- 2007-11-23 RU RU2009123409/10A patent/RU2451689C2/ru not_active IP Right Cessation
- 2007-11-23 WO PCT/EP2007/062760 patent/WO2008062063A1/en not_active Ceased
- 2007-11-23 CA CA002670039A patent/CA2670039A1/en not_active Abandoned
- 2007-11-24 SA SA07280637A patent/SA07280637B1/ar unknown
- 2007-11-26 TW TW096144763A patent/TW200829602A/zh unknown
-
2008
- 2008-05-22 US US12/125,726 patent/US8071730B2/en not_active Expired - Fee Related
-
2009
- 2009-05-06 NI NI200900079A patent/NI200900079A/es unknown
- 2009-05-08 CR CR10788A patent/CR10788A/es unknown
- 2009-05-14 CU CU20090082A patent/CU23792A3/es not_active IP Right Cessation
- 2009-05-14 IL IL198744A patent/IL198744A0/en unknown
- 2009-05-14 MA MA31875A patent/MA30891B1/fr unknown
- 2009-05-14 GT GT200900126A patent/GT200900126A/es unknown
- 2009-05-18 EC EC2009009341A patent/ECSP099341A/es unknown
- 2009-05-18 TN TNP2009000194A patent/TN2009000194A1/fr unknown
- 2009-06-19 NO NO20092360A patent/NO20092360L/no not_active Application Discontinuation
-
2011
- 2011-12-05 US US13/310,840 patent/US20120156191A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107151269B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| JP2022079549A5 (enExample) | ||
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| AU2023203119A1 (en) | Cd20 binding molecules and uses thereof | |
| TWI854953B (zh) | 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法 | |
| CN102421802B (zh) | 人源化的axl抗体 | |
| JP2021524268A5 (enExample) | ||
| JP2018161141A (ja) | ヘテロ多量体分子を作製するための方法 | |
| JP2010532982A5 (enExample) | ||
| JP2019501883A5 (enExample) | ||
| JP2021510521A5 (enExample) | ||
| JP2018502050A5 (enExample) | ||
| JP2013056885A5 (enExample) | ||
| JP2012504401A5 (enExample) | ||
| JP2010524435A5 (enExample) | ||
| HRP20140502T1 (hr) | Humanizirana anti-cxcr4 antitijela za lijeäśenje karcinoma | |
| US20240294622A1 (en) | Novel anti-gremlin1 antibodies | |
| JP2010504743A5 (enExample) | ||
| JP2023543493A5 (enExample) | ||
| JP2023518153A5 (enExample) | ||
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| CN111479827B (zh) | 结合hERG1和hERG1/整联蛋白β1的单特异性和双特异性抗体 | |
| CN120554510B (zh) | 抗钙粘蛋白-17的双表位抗体及采用其制备的抗体药物偶联物 | |
| NZ779636A (en) | Claudin-6 antibodies and drug conjugates |